top of page

NCI-2018-02927

Phase I/II Trial of Leflunomide in Women with Previously Treated

Metastatic Triple Negative Cancer


This is a research study that has two parts, or "phases." The study is looks at a medicine called Leflunomide and how it might help women who have a specific type of breast cancer called metastatic triple-negative breast cancer. In the first phase of the study, they test the medicine's safety and how well people can tolerate it. They start with a small dose and then gradually increase it if it seems safe. They want to make sure it doesn't cause too many side effects. In the second phase, they will look more closely at how effective the medicine is in treating this type of cancer. They'll pay attention to things like how much the cancer shrinks, how long people live without their cancer getting worse, and how the participants feel while taking the medicine.

Metastatic: a cancer that has spread from its original location or organ to other parts of the body.

Triple-negative breast cancer: a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

NCI-2018-02927

Clinical Trial Site: Mount Sinai


To see all available clinical trials click here.

Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Doctors are conducting a study to test the safety and effectiveness of a new medicine called

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

bottom of page